For over four decades, the Ki67 immunohistochemistry (IHC) has played a significant role in assessing cellular proliferation in BC and other solid tumors, providing important prognostic and potentially predictive insights for antineoplastic therapies [8]. This evidence concerns the gene MKI67 and breast cancer.